menu
    • menu
    [{"orgOrder":0,"company":"PentixaPharm","sponsor":"Pivotal S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"68-Ga Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Pivotal S.L.","highestDevelopmentStatusID":"10","companyTruncated":"PentixaPharm \/ Pivotal S.L."},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"68-Ga Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ PentixaPharm","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ PentixaPharm"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"90-Y PentixaTher","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Elsa Eckert Life Science Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Peptide, Unconjugated","year":"2020","type":"Series A Financing","leadProduct":"Pentixafor","moa":"CXCR-4 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Elsa Eckert Life Science Accelerator","highestDevelopmentStatusID":"6","companyTruncated":"PentixaPharm \/ Elsa Eckert Life Science Accelerator"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Glycotope","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"GT-001","moa":"Neuropeptide Y receptor type 2","graph1":"Oncology","graph2":"Preclinical","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ PentixaPharm","highestDevelopmentStatusID":"4","companyTruncated":"PentixaPharm \/ PentixaPharm"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"68-Ga PTF","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Myelo001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PentixaPharm \/ Undisclosed"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"BankM AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Y90-PentixaTher","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"PentixaPharm \/ BankM AG","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ BankM AG"},{"orgOrder":0,"company":"PentixaPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu PentixaTher","moa":"CXCR4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PentixaPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PentixaPharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PentixaPharm \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by PentixaPharm

    Menu

    PentixaPharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pentixapharm Advances PentixaTher to Fourth Dose in AML Trial

                            Details : Company's s CXCR4-targeting radiolabeled candidate PentixaTher has advanced to the fourth dose level in the investigator-initiated pentilula Phase 1/2 study in acute myeloid leukemia (AML).

                            Product Name : PentixaTher

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            September 26, 2025

                            Lead Product(s) : 177-Lu PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lu177-PentixaTher Trial Begins for AML and ALL, Supporting Radiotherapy Evidence

                            Details : Lu177-PentixaTher is a novel radiopharmaceutical therapy, being investigated in adults for relapsed/refractory CXCR4 positive acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 21, 2024

                            Lead Product(s) : 177-Lu PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Y90-PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BankM AG

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Pentixapharm Scores $22M in IPO to Advance Radiopharma Trials

                            Details : The proceeds will focus on the clinical development and approval of company's lead candidates Ga68-PentixaFor and Y90-PentixaTher.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 03, 2024

                            Lead Product(s) : Y90-PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BankM AG

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GT-001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pentixapharm Acquires Target Discovery Business of Glycotope

                            Details : Through the acquisition, Pentixapharm will leverage the Glycotype portfolio of preclinical antibodies against multiple oncology including GT-001, which is being evaluated for breast and lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 03, 2024

                            Lead Product(s) : GT-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Glycotope

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 90-Y PentixaTher

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

                            Details : 90-Y PentixaTher is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            November 15, 2023

                            Lead Product(s) : 90-Y PentixaTher

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga Pentixafor

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Pivotal S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma

                            Details : 68-Ga Pentixafor is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, B-Cell, Marginal Zone.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : 68-Ga Pentixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Pivotal S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga PTF

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

                            Details : 68-Ga PTF is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            February 03, 2022

                            Lead Product(s) : 68-Ga PTF

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga Pentixafor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

                            Details : 68-Ga Pentixafor is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, Non-Hodgkin.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            October 26, 2021

                            Lead Product(s) : 68-Ga Pentixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Memorial Sloan Kettering Cancer Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentixafor

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Elsa Eckert Life Science Accelerator

                            Deal Size : $16.2 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            PENTIXAPHARM Secures € 15 Million Series A Financing

                            Details : Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : Pentixafor

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Elsa Eckert Life Science Accelerator

                            Deal Size : $16.2 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            PentixaPharm

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Myelo001

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

                            Details : Myelo001 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chemotherapy-induced Neutropenia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 26, 2016

                            Lead Product(s) : Myelo001

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth